（文章来源：证券日报） 证券日报网讯 2月27日，建发致新发布公告称，中信证券作为公司首次公开发行股票并在深圳证券交易 所创业板上市项目的保荐人，原委派张磊、王琦作为公司首次公开发行股票并在创业板上市项目持续督 导保荐代表人。2026年2月，因王琦工作变动，不再负责公司持续督导工作。为继续履行持续督导义 务，中信证券委派保荐代表人沈子权接替王琦担任公司首次公开发行股票并在创业板上市项目持续督导 保荐代表人，负责公司首次公开发行股票并在创业板上市项目的持续督导工作。本次变更后，公司首次 公开发行股票并在创业板上市项目持续督导保荐代表人为张磊、沈子权，持续督导期至中国证券监督管 理委员会和深交所规定的持续督导义务结束为止。 ...

证券代码：301584 证券简称：建发致新 公告编号：2026-005 上海建发致新医疗科技集团股份有限公司 关于变更保荐代表人的公告 上海建发致新医疗科技集团股份有限公司董事会 2026 年 2 月 27 日 附件：沈子权先生个人简历 沈子权先生，保荐代表人，现任中信证券投资银行管理委员会副总裁。自从 事投资银行业务以来，曾负责或参与了建发致新、长风药业、海创药业、科美诊 断、共同药业、长沙银行等 IPO 项目以及海思科再融资、大博医疗再融资、中国 船舶重大资产重组等项目，在保荐业务执业过程中严格遵守《证券发行上市保荐 业务管理办法》等相关规定，执业记录良好。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，上海建发致新医疗科技集团股份有限公司（以下简称"公司"）收到 中信证券股份有限公司（以下简称"中信证券"）《上海建发致新医疗科技集团 股份有限公司首次公开发行股票并在创业板上市项目持续督导变更保荐代表人 的说明》，公司保荐代表人变更的具体情况如下： 中信证券作为公司首次公开发行股票并在深圳证券交易所（以下简称"深交 所"）创业板上市项目的保荐人，原 ...

Group 1 - On February 12, Jianda Zhixin's stock price fell by 1.37%, with a trading volume of 66.01 million yuan [1] - The financing data for Jianda Zhixin on the same day showed a financing purchase amount of 5.46 million yuan and a financing repayment of 10.02 million yuan, resulting in a net financing buy of -4.56 million yuan [1] - As of February 12, the total balance of margin trading for Jianda Zhixin was 92.45 million yuan, accounting for 6.39% of its circulating market value [1] Group 2 - As of December 31, Jianda Zhixin had 25,900 shareholders, a decrease of 10.35% from the previous period, while the average circulating shares per person increased by 11.55% to 1,949 shares [2] - For the period from January to September 2025, Jianda Zhixin reported an operating income of 14.861 billion yuan, representing a year-on-year growth of 10.18%, and a net profit attributable to shareholders of 230 million yuan, which is a 45.01% increase year-on-year [2]

证券代码：301584 证券简称：建发致新 公告编号：2026-004 上海建发致新医疗科技集团股份有限公司 关于为下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 上海建发致新医疗科技集团股份有限公司（以下简称"公司"或"建发致 新"）及控股子公司提供担保总额超过公司最近一期经审计净资产100%，对资产 负债率超过70%的控股子公司预计担保金额超过公司最近一期经审计净资产50%， 前述担保均为对公司合并报表范围内子公司的担保，财务风险处于公司可控范围内， 提请投资者充分关注担保风险。 一、对外担保情况概述 根据公司经营发展战略、资金预算和资金安全等需要，自公司2024年年度股东 大会之日起，至2025年年度股东会召开之日止，公司及控股子公司拟向各银行等金 融机构申请综合授信总额不超过人民币150亿元，以上事项已经公司2024年年度股东 大会和2025年第二次临时股东大会审议通过。 鉴于上述授信总额中部分授信额度的融资主体为公司控股子公司，为保障子公 司顺利申请授信额度，自公司2024年年度股东大会之日起，至2025 ...

Group 1 - The core viewpoint of the news is that Jianfa Zhixin experienced a slight decline in stock price and trading volume on February 6, with a net financing outflow reported [1] - On February 6, Jianfa Zhixin's financing buy amounted to 2.09 million yuan, while financing repayment was 3.29 million yuan, resulting in a net financing buy of -1.19 million yuan [1] - As of February 6, the total financing and securities balance for Jianfa Zhixin was 99.70 million yuan, accounting for 6.75% of its market capitalization [1] Group 2 - As of December 31, Jianfa Zhixin had 25,900 shareholders, a decrease of 10.35% compared to the previous period [2] - The average number of circulating shares per shareholder increased by 11.55% to 1,949 shares [2] - For the period from January to September 2025, Jianfa Zhixin reported operating revenue of 14.861 billion yuan, a year-on-year increase of 10.18%, and a net profit attributable to shareholders of 230 million yuan, reflecting a 45.01% year-on-year growth [2]

Core Viewpoint - The resignation of non-independent director Wang Wenhui from the board of Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. is confirmed, and it will not affect the company's operations or board composition [1][2]. Group 1: Resignation Details - Wang Wenhui submitted a written resignation due to personal work reasons, resigning from his position as a director and a member of the Strategic Committee of the third board [1]. - His resignation is effective immediately upon delivery to the board and will not lead to a reduction in the number of board members below the legal minimum [1][2]. Group 2: Company Response - The company expresses gratitude for Wang Wenhui's contributions during his tenure and confirms that he has no shares in the company at the time of his resignation [2]. - The company will proceed with the necessary procedures to elect a new non-independent director in accordance with relevant laws and regulations [2].

证券代码：301584 证券简称：建发致新 公告编号：2026-003 上海建发致新医疗科技集团股份有限公司 关于公司董事辞职的公告 鉴于王文怀先生辞去公司董事职务未导致公司董事会成员低于法定最低人 数，根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及《公司章程》等相关规定，王文怀先生的 辞职不会对公司经营和董事会运作产生影响。王文怀先生的辞职报告自送达董事 会之日起生效，其原定任期至第三届董事会届满之日止。 截至本公告披露日，王文怀先生未持有公司股票，辞职后将继续履行其在公 司首次公开发行股票并上市时作出的各项仍在履行期限内的承诺，除此之外不存 在其他应履行而未履行的承诺。同时，王文怀先生已按照《董事、高级管理人员 离职管理制度》做好离职交接工作，公司将按照相关法律法规及《公司章程》有 关规定尽快完成公司非独立董事的补选工作。 王文怀先生在公司担任董事期间，恪尽职守、勤勉尽责，公司及公司董事会 对其在任职期间为公司发展作出的贡献表示衷心感谢！ 特此公告。 上海建发致新医疗科技集团股份有限公司董事会 2026 年 1 月 20 日 本公司及董事会全体成员 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.48% on January 20, with Luyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Guofa Co., Ltd. (600538) with a closing price of 6.87, up 3.46% and a trading volume of 245,400 shares, totaling 168 million yuan [1] - Huaren Health (301408) closed at 22.08, up 1.38% with a trading volume of 317,600 shares, totaling 700 million yuan [1] - Conversely, significant decliners included: - Jianghe Pharmaceutical (002788) with a closing price of 16.64, down 6.04% and a trading volume of 872,500 shares, totaling 1.465 billion yuan [2] - Yingte Group (000411) closed at 13.84, down 2.40% with a trading volume of 230,300 shares, totaling 316 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 497 million yuan from institutional investors and a net outflow of 109 million yuan from speculative funds, while retail investors had a net inflow of 607 million yuan [2] - Key stocks with notable capital flows included: - Huaren Health (301408) with a net inflow of 46.16 million yuan from institutional investors, but a net outflow of 48.48 million yuan from retail investors [3] - Yifeng Pharmacy (603939) had a net inflow of 21.74 million yuan from institutional investors, but also saw a net outflow of 1.63 million yuan from retail investors [3]

Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. (referred to as "Jianda Zhixin") expects a positive increase in net profit for the fiscal year 2025, with projections indicating a net profit of between 242 million to 296 million yuan, representing a year-on-year growth of 6.00% to 29.65% [1] Group 1 - The expected net profit attributable to shareholders is projected to be between 232 million to 286 million yuan, with a year-on-year increase of 3.77% to 27.93% [1] - The growth in Jianda Zhixin's 2025 performance is attributed to two main factors: the rapid development of its core business in centralized operation of medical consumables (SPD), which has a high gross profit margin, enhancing overall profitability [1] - The company has optimized its financial structure, resulting in a year-on-year decrease in interest-bearing liabilities and reduced financing costs through negotiations with financial institutions, positively impacting net profit [1] Group 2 - Jianda Zhixin primarily engages in the direct sales and distribution of medical devices, providing centralized operation services for medical consumables (SPD) to end hospitals [1] - The company's direct sales and distribution products mainly include vascular interventional devices, surgical instruments, IVD (in vitro diagnostic) products, and medical equipment [1]

Group 1 - The company, Shanghai Jianda Zhixin Medical Technology Group Co., Ltd., has issued a voluntary performance forecast for the fiscal year 2025, indicating that the net profit attributable to shareholders is expected to be positive and show an upward trend [1][3] - The performance forecast period is from January 1, 2025, to December 31, 2025 [1] - The company has communicated with its auditing firm regarding the performance forecast, and there are no discrepancies between the company and the auditors [2] Group 2 - The company's medical consumables centralized operation (SPD) business is experiencing rapid growth, contributing to an increase in overall profitability due to its high gross profit margin [3] - The company has optimized its financial structure, resulting in a year-on-year decrease in interest-bearing debt and a reduction in financing costs through negotiations with financial institutions, positively impacting net profit [3]